ArticleOral oncology2013
A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma.
Article in Oral oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- EMMPRIN expression in oral squamous cell carcinomas: correlation with tumor proliferation and patient survival.BioMed research international · 2014Trial
- Mini-Review: Can the Metastatic Cascade Be Inhibited by Targeting CD147/EMMPRIN to Prevent Tumor Recurrence?Frontiers in immunology · 2022Review
- Activation of a G protein-coupled receptor through indirect antibody-mediated tethering of ligands.RSC chemical biology · 2021Article
- Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review.Cancers · 2021Review
- Strategies for targeting cell surface proteins using multivalent conjugates and chemical biology.Methods in cell biology · 2021Article
- Knockdown of lncRNA BLACAT1 enhances radiosensitivity of head and neck squamous cell carcinoma cells by regulating PSEN1.The British journal of radiology · 2020Article
- CD147 and Cyclooxygenase Expression in Feline Oral Squamous Cell Carcinoma.Veterinary sciences · 2018Article
- Structure-guided Discovery of Dual-recognition Chemibodies.Scientific reports · 2018Article
- Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Targeting CD147 for T to NK Lineage Reprogramming and Tumor Therapy.EBioMedicine · 2017Article
- Review
- Influence of Sugar Amine Regiochemistry on Digitoxigenin Neoglycoside Anticancer Activity.ACS medicinal chemistry letters · 2015Article
- Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection.The AAPS journal · 2015Review
- The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature.International journal of molecular sciences · 2014Review
- Prostate cancer relevant antigens and enzymes for targeted drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2014Review
- Neoglycosylation and neoglycorandomization: Enabling tools for the discovery of novel glycosylated bioactive probes and early stage leads.MedChemComm · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesDespite advances in treatment modalities, head and neck squamous cell carcinoma (HNSCC) remains a challenge to treat with poor survival and high morbidity, necessitating a therapy with greater efficacy. EDC22 is an extracellular drug conjugate of the monoclonal antibody targeting CD147 (glycoprotein highly expressed on HNSCC cells) linked with a small drug molecule inhibitor of Na, K-ATPase. In this study, EDC22's potential as a treatment modality for HNSCC was performed. MATERIALS AND
methodsHNSCC cell lines (FADU, OSC-19, Cal27, SCC-1) were cultured in vitro and proliferation and cell viability were assessed following treatment with a range of concentrations of EDC22 (0.25-5.00μg/mL). Mice bearing HNSCC xenografts (OSC-19, SCC-1) were treated with either EDC22 (3-10mg/kg), anti-CD147 monoclonal antibody, cisplatin (1mg/kg) or radiation therapy (2Gy/week) monotherapy or in combination.
resultsIn vitro, treatment with minimal concentration of EDC22 (0.25μg/mL) significantly decreased cellular proliferation and cell viability (p<0.0001). In vivo, systemic treatment with EDC22 significantly decreased primary tumor growth rate in both an orthotopic mouse model (OSC-19) and a flank tumor mouse model (SCC-1) (p<0.05). In addition, EDC22 therapy resulted in a greater reduction in tumor growth in vivo compared to radiation monotherapy (p<0.05) and a similar reduction in tumor growth compared to cisplatin monotherapy. Combination therapy provided no significant further reduction in tumor growth relative to EDC22 monotherapy.
conclusionEDC22 is a potent inhibitor of HNSCC cell proliferation in vitro and in vivo, warranting further investigations of its clinical potential in the treatment of HNSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.